[go: up one dir, main page]

WO2015001489A1 - Compositions pharmaceutiques de ticagrélor - Google Patents

Compositions pharmaceutiques de ticagrélor Download PDF

Info

Publication number
WO2015001489A1
WO2015001489A1 PCT/IB2014/062773 IB2014062773W WO2015001489A1 WO 2015001489 A1 WO2015001489 A1 WO 2015001489A1 IB 2014062773 W IB2014062773 W IB 2014062773W WO 2015001489 A1 WO2015001489 A1 WO 2015001489A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
ticagrelor
composition according
tablets
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2014/062773
Other languages
English (en)
Inventor
Radhanath Mandal
Mona Dhaliwal
Swati Agarwal
Mukesh Kumar Garg
Ajay Kumar Singla
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2015001489A1 publication Critical patent/WO2015001489A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Definitions

  • the present invention relates to oral pharmaceutical compositions comprising amorphous ticagrelor and processes for their preparation. It further relates to a method of treating cardiovascular diseases using said pharmaceutical compositions.
  • Ticagrelor is a P2Yn platelet inhibitor. Chemically it is (l ⁇ S i ⁇ -S-f?- ⁇ [(li?,25)-2-(3,4-difluorophenyl)cyclopropyl]amino ⁇ -5-(propylthio)-3H-[l,2,3]- triazolo[4,5-£/]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol.
  • Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 ⁇ g/mL at room temperature.
  • PCT Publication No. WO 00/34283 discloses ticagrelor as a compound and U.S. Patent No. 7,265, 124 discloses various polymorphs of ticagrelor.
  • U.S. Patent No. 8,425,934 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising ticagrelor, a filler consisting essentially of a mixture of mannitol and dibasic calcium phosphate dihydrate, a binder consisting essentially of hydroxypropyl cellulose, a disintegrant consisting essentially of sodium starch glycolate, and one or more lubricants.
  • the compositions are prepared by using a wet granulation process.
  • U.S. Publication No. 2008/0045548 discloses a pharmaceutical composition of ticagrelor suitable for oral administration that releases substantially all of the drug substance.
  • WO 2011/076749 discloses solid dosage forms comprising ticagrelor, characterized in that at least 90% by volume of ticagrelor particles have a particle size in the range of 1 ⁇ to 150 ⁇ . It further discloses that ticagrelor, being poorly soluble, presents a significant problem in the design of pharmaceutical compositions. Further, in order to exhibit good bioavailability, it is desirable to formulate dosage forms showing fast dissolution of the drug. This can be achieved by reducing the particle size of the drug and by the use of hydrophilic polymers/emulsifiers in the dosage form. According to the Biopharmaceutics Classification System (BCS), ticagrelor is classified as a class IV compound, exhibiting low solubility and low permeability. This property leads to an undesirable dissolution profile and hence poor bioavailability. It also leads to high intra-subject and inter-subject variability following oral administration.
  • BCS Biopharmaceutics Classification System
  • the amorphous form of a drug has higher solubility as compared to the crystalline form.
  • the use of the amorphous form poses many challenges during formulation of the dosage form as the amorphous form is generally more hygroscopic and less stable than the crystalline form.
  • the present application discloses that the dissolution of ticagrelor can be improved by using the drug in its amorphous form.
  • the present invention provides an alternate pharmaceutical composition comprising ticagrelor in a stable and readily bioavailable form.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition provides a desirable dissolution profile and enhanced bioavailability.
  • the pharmaceutically acceptable excipients further comprise diluents, binders, disintegrants, and lubricants.
  • the present invention also includes different processes for the preparation of said pharmaceutical composition and a method of treating cardiovascular diseases by administering said pharmaceutical composition.
  • pharmaceutically acceptable excipients includes diluents, binders, disintegrants, lubricants, glidants, stabilizers, surfactants, solubility enhancers, coloring agents, flavoring agents, plasticizers, opacifiers, or mixtures thereof.
  • solid dispersion refers to a group of solid products consisting of at least two different components, generally a hydrophilic matrix or a carrier/stabilizer and a hydrophobic drug.
  • the matrix can be either crystalline or amorphous.
  • the drug can be dispersed molecularly, in amorphous particles (clusters), or in crystalline particles,
  • a first aspect of the present invention provides a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients selected from one or more diluents, binders, disintegrants, lubricants, glidants, stabilizers, surfactants, solubility enhancers, coloring agents, flavoring agents, plasticizers, opacifiers, or mixtures thereof.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients selected from diluents, binders, disintegrants, lubricants, or mixtures thereof.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the diluent is not mannitol and/or dibasic calcium phosphate dihydrate.
  • the composition is free of mannitol and/or dibasic calcium phosphate dihydrate.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the binder is not hydroxypropyl cellulose.
  • the composition is free of hydroxypropyl cellulose.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the disintegrant is not sodium starch glycolate.
  • the composition is free of sodium starch glycolate.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the diluent is not mannitol and/or dibasic calcium phosphate dihydrate, the binder is not hydroxypropyl cellulose, and the disintegrant is not sodium starch glycolate.
  • the composition is free of mannitol, dibasic calcium phosphate dehydrate, hydroxypropyl cellulose and sodium starch glycolate.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the binder is povidone and the disintegrant is croscarmellose sodium.
  • a pharmaceutical composition comprising a solid dispersion of amorphous ticagrelor, one or more hydrophilic polymers, and optionally one or more pharmaceutically acceptable excipients.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients, wherein the composition further comprises one or more other anti -thrombotic agents.
  • the water content of the final composition of the present invention is not more than 5.0% w/w.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the composition is prepared by direct compression or dry granulation.
  • a pharmaceutical composition comprising amorphous ticagrelor and one or more diluents, binders, disintegrants, and lubricants, wherein the composition is prepared by hot melt extrusion.
  • a second aspect of the present invention provides a process for the preparation of a pharmaceutical composition of the present invention, wherein the process comprises the steps of:
  • a third aspect of the present invention provides a process for the preparation of the pharmaceutical composition of the present invention, wherein the process comprises the steps of:
  • diluents binders, disintegrants, and/or lubricants can also be added extragranularly.
  • a fourth aspect of the present invention provides a process for the preparation of a pharmaceutical composition of the present invention, wherein the process comprises the steps of:
  • a surfactant in a rapid mixer granulator optionally a surfactant in a rapid mixer granulator
  • step (b) loading the granules obtained in step (a) into a hot melt extruder to form a solid dispersion in the form of extrudates;
  • a fifth aspect of the present invention provides a method of treating cardiovascular diseases by administering a pharmaceutical composition comprising amorphous ticagrelor and one or more pharmaceutically acceptable excipients.
  • cardiovascular diseases refers to thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease.
  • ACS acute coronary syndrome
  • the method of treatment further comprises administration of an additional anti-thrombotic agent.
  • Suitable diluents are selected from the group consisting of lactose, microcrystalline cellulose, co-processed microcrystalline cellulose, powdered cellulose, crospovidone, co- povidone, mannitol, sorbitol, xylitol, erythritol, dibasic calcium phosphate, dibasic calcium phosphate anhydrate, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, calcium sulfate, calcium carbonate, pregelatinized starch, maize starch, corn starch, or mixtures thereof.
  • the present invention comprises one or more diluents in an amount of from about 5% to about 90% by weight of the composition.
  • Suitable binders are selected from the group consisting of povidone, co-povidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose sodium, xanthan gum, gum acacia, gum arabic, tragacanth, sorbitol, dextrose, sucrose, mannitol, gelatin, pullulan, sodium alginate, propylene glycol, polyvinyl alcohol, corn starch, maize starch, pregelatinized starch, methacrylates, carboxyvinyl polymers like carbomers, or mixtures thereof.
  • the present invention comprises one or more binders in an amount of from about 0.5% to about 30% by weight of the composition.
  • Suitable disintegrants are selected from the group consisting of hydroxypropyl cellulose, crospovidone, croscarmellose sodium, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, sodium starch glycolate, gums, alginic acid or alginates, starch, corn starch, modified starch, carboxymethyl starch, polyacrylates, or mixtures thereof.
  • the present invention comprises one or more disintegrants in an amount of from about 0.5% to about 30% by weight of the composition.
  • Suitable lubricants are selected from the group consisting of stearic acid, polyethylene glycol, magnesium stearate, calcium stearate, talc, zinc stearate,
  • Suitable glidants are selected from the group consisting of colloidal silicon dioxide, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc, or mixtures thereof.
  • Suitable stabilizers are selected from the group consisting of cellulose derivatives such as hydroxypropyl methylcellulose, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose phthalate, carboxymethylcellulose sodium, and carboxymethylcellulose calcium; polyvinylpyrrolidone and/or derivatives thereof, such as co-povidone; polyvinyl alcohol; polyethylene glycol; block copolymers of ethylene oxide and/or propylene oxide; gums such as xanthan gum, pectins, alginates, tragacanth and/or derivatives thereof, and gum arabic and/or derivatives thereof; carrageenans, agar and/or derivatives thereof; polysaccharides from microbiological sources; acacia; starch;
  • the stabilizers may also act as crystallization inhibitors.
  • Suitable surfactants are selected from the group consisting of sodium lauryl sulfate, sodium dodecyl sulfate, ammonium lauryl sulfate, benzalkonium chloride, alkyl poly (ethylene oxide), copolymers of poly (ethylene oxide) and poly (propylene oxide) commercially called as poloxamers or poloxamines, polyvinyl alcohol (PVA), fatty alcohols, polyoxyethylene alkyl ether, polyoxyethylene alkylaryl ether, polyethylene glycol fatty acid ester, alkylene glycol fatty acid mono ester, sucrose fatty acid ester, and sorbitan fatty acid mono ester, sorbitol monolaurate (Span ® 20 or Span ® 80),
  • polysorbates polyoxyethylene sorbitan fatty acid ester (polysorbates), or mixtures thereof.
  • Suitable solubility enhancers are selected from the group consisting of sodium lauryl sulfate, polyethylene glycol, propylene glycol, glycerol, glycerol monostearate, glycerol behenate, triglycerides, mono-alcohols, higher alcohols, dimethylsulfoxide, dimethylformamide, N,N-dimethylacetamide, N-methyl-2-pyrrolidone, N-(2- hydroxyethyl) pyrrolidone, 2-pyrrolidone, or mixtures thereof.
  • Suitable coloring agents and flavoring agents are selected from any FDA approved colors and flavors for oral use.
  • Suitable plasticizers are selected from the group consisting of triethyl citrate, dibutyl sebacate, acetylated triacetin, tributyl citrate, glyceryl tributyrate, sorbitol monolaurate (Span ® 20), monoglyceride, rapeseed oil, olive oil, sesame oil, acetyl tributyl citrate, acetyl triethyl citrate, glycerin sorbitol, diethyl oxalate, diethyl phthalate, diethyl malate, diethyl fumarate, dibutyl succinate, diethyl malonate, dioctyl phthalate, or mixtures thereof.
  • Suitable opacifiers are selected from the group consisting of titanium dioxide, manganese dioxide, iron oxide, silicon dioxide, or mixtures thereof.
  • Suitable hydrophilic polymers are selected from the group consisting of polyvinyl alcohol (PVA), polyvinylpyrrolidone, co-povidone, vinyl acetate polymer, polyalkylene oxide, polyoxyethylene stearates, polyacrylate, polymethacrylate, pluronics,
  • polyacrylamide a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, homopolymer of N-vinyl lactam, copolymer of N-vinyl lactam, oligosaccharide, polysaccharide, cellulose such as cellulose ester, cellulose ether, or mixtures thereof.
  • the pharmaceutical composition of the present invention can be obtained by using known conventional methods, i.e., granulation or direct compression.
  • the granulation process includes, but is not limited to, wet granulation, dry granulation, hot melt granulation, hot melt extrusion, or solvent evaporation.
  • composition of the present invention may be in the form of minitablets, granules, pellets, tablets, or capsules.
  • the pharmaceutical composition of the present invention may further be film-coated using techniques well known in the art such as spray coating in a conventional coating pan or a fluidized bed processor or dip coating.
  • coating may also be performed using the hot melt technique.
  • the film coat comprises film-forming polymers and one or more pharmaceutically acceptable excipients.
  • film-forming agents include, but are not limited to, cellulose derivatives such as methylcellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethyl ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and ethyl cellulose; waxes; fat substances; or mixtures thereof.
  • commercially available coating compositions comprising film forming polymers marketed under various trade names, such as Opadry ® , may be used for coating.
  • solvents used for preparing the coating solution are selected from methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, water, or mixtures thereof.
  • the pharmaceutical composition of the present invention is useful for the treatment of cardiovascular diseases such as thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease in patients with acute coronary syndrome (ACS).
  • cardiovascular diseases such as thrombotic cardiovascular events selected from unstable angina, myocardial infarction, stroke, transient ischaemic attacks, or peripheral vascular disease in patients with acute coronary syndrome (ACS).
  • ACS acute coronary syndrome
  • the pharmaceutical composition of the present invention may be administered along with an additional anti-thrombotic agent.
  • the other anti-thrombotic agent is selected from anti-platelet agents such as ASA (acetylsalicylic acid), clopidogrel, ticlopidine, dipyridamole, and GPIIb/llla antagonists; anticoagulant agents such as thrombin inhibitors, warfarin, factor Xa inhibitors, and heparin; and fibrinolytic agent such as streptokinase and tenecteplase.
  • anti-platelet agents such as ASA (acetylsalicylic acid), clopidogrel, ticlopidine, dipyridamole, and GPIIb/llla antagonists
  • anticoagulant agents such as thrombin inhibitors, warfarin, factor Xa inhibitors, and heparin
  • fibrinolytic agent such as streptokinase and tenecteplase.
  • Ticagrelor, crospovidone, povidone, and croscarmellose sodium are blended in a blender.
  • step 1 The blend of step 1 is lubricated with magnesium stearate and compressed into tablets.
  • step 2 The tablets of step 2 are coated with an Opadry ® dispersion.
  • Example 2
  • Ticagrelor, lactose monohydrate, povidone, and croscarmellose sodium are blended in a blender.
  • step 1 The blend of step 1 is lubricated with magnesium stearate and compressed into tablets.
  • step 2 The tablets of step 2 are coated with an Opadry ® dispersion.
  • Ticagrelor, microcrystalline cellulose, povidone, and croscarmellose sodium are blended in a blender.
  • step 1 The blend of step 1 is lubricated with magnesium stearate and compressed into tablets.
  • step 2 The tablets of step 2 are coated with an Opadry ® dispersion.
  • Example 4
  • Ticagrelor, mannitol, dibasic calcium phosphate dihydrate, sodium starch glycolate, hydroxypropyl methylcellulose, and a part of magnesium stearate are blended in a blender.
  • step 1 The blend of step 1 is dry granulated by compaction to obtain a 60:40 ratio of granules: fines.
  • step 2 The blend of step 2 is lubricated with the remaining part of magnesium stearate and compressed into tablets.
  • step 3 The tablets of step 3 are coated with an Opadry ® dispersion.
  • Ticagrelor, mannitol, dibasic calcium phosphate dihydrate, sodium starch glycolate, hydroxypropyl cellulose, and a part of magnesium stearate are blended in a blender.
  • the blend of step 1 is dry granulated by compaction to obtain a 60:40 ratio of granules: fines.
  • step 2 The blend of step 2 is lubricated with the remaining part of magnesium stearate and compressed into tablets.
  • step 3 The tablets of step 3 are coated with an Opadry ® dispersion.
  • Ticagrelor and co-povidone are mixed together.
  • Sorbitol monolaurate is added to the blend of step 1 and the blend is loaded into a rapid mixer granulator to obtain granules.
  • step 2 The granules obtained from step 2 are loaded into a hot melt extruder and the extrudate/sheet obtained is milled.
  • step 4 Sodium starch glycolate, hydroxypropyl cellulose, microcrystalline cellulose, and magnesium stearate are added to the milled extrudates of step 3 and blended. The blend of step 4 is compressed into tablets.
  • step 5 The tablets of step 5 are coated with an Opadry ® dispersion.
  • Example 7 The tablets of step 5 are coated with an Opadry ® dispersion.
  • Ticagrelor, mannitol, dibasic calcium phosphate dihydrate, croscarmellose sodium, and hydroxypropyl cellulose were blended in a blender.
  • step 1 The blend of step 1 was lubricated with magnesium stearate and compressed into tablets.
  • step 2 The tablets of step 2 were coated with an Opadry ® dispersion.
  • Ticagrelor, mannitol, 2/3 of the croscarmellose sodium, hydroxypropyl cellulose, and 4/7 of the magnesium stearate were blended in a blender.
  • step 2 The blend of step 1 was dry granulated by compaction to obtain a 60:40 ratio of granules: fines.
  • step 3 Dibasic calcium phosphate dihydrate and the remaining part of croscarmellose sodium were sifted and blended with the blend of step 2. 4. The blend of step 3 was lubricated with the remaining part of magnesium stearate and compressed into tablets.
  • step 4 The tablets of step 4 were coated with an Opadry ® dispersion.
  • Ticagrelor, mannitol, dibasic calcium phosphate dihydrate/ anhydrous, povidone, croscarmellose sodium, and pregelatinized starch were blended in a blender.
  • step 1 The blend of step 1 was lubricated with magnesium stearate and compressed into tablets.
  • step 2 The tablets of step 2 were coated with an Opadry ® dispersion.
  • Ticagrelor, mannitol, half of the croscarmellose sodium and 4/7 of the magnesium stearate were blended in a blender.
  • step 2 The blend of step 1 was dry granulated by compaction to obtain a 60:40 ratio of granules: fines.
  • step 3 The blend of step 3 was lubricated with the remaining part of magnesium stearate and compressed into tablets.
  • step 4 The tablets of step 4 were coated with an Opadry ® dispersion.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques orales comprenant du ticagrélor amorphe et des procédés pour leur préparation. L'invention porte en outre sur une méthode de traitement de maladies cardiovasculaires utilisant lesdites compositions pharmaceutiques.
PCT/IB2014/062773 2013-07-01 2014-07-01 Compositions pharmaceutiques de ticagrélor WO2015001489A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1948/DEL/2013 2013-07-01
IN1948DE2013 2013-07-01

Publications (1)

Publication Number Publication Date
WO2015001489A1 true WO2015001489A1 (fr) 2015-01-08

Family

ID=51176430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/062773 WO2015001489A1 (fr) 2013-07-01 2014-07-01 Compositions pharmaceutiques de ticagrélor

Country Status (1)

Country Link
WO (1) WO2015001489A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
WO2017182455A1 (fr) 2016-04-18 2017-10-26 Amneal Pharmaceuticals Company Gmbh Composition pharmaceutique stable de ticagrelor amorphe
CN107397717A (zh) * 2017-09-13 2017-11-28 冯威 一种替卡格雷或其药学上可接受盐的固体制剂
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
EP3332769A1 (fr) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques orales solides de ticagrelor
WO2019170244A1 (fr) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Formulation de comprimé contenant du ticagrelor
CN110507624A (zh) * 2018-05-22 2019-11-29 江苏恒瑞医药股份有限公司 一种替格瑞洛或其盐的控释组合物
WO2020021110A1 (fr) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Composition pharmaceutique de ticagrélor
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034283A1 (fr) 1998-12-04 2000-06-15 Astrazeneca Ab Nouveaux composes de triazolo(4,5-d)pyrimidine
WO2001092262A1 (fr) * 2000-06-02 2001-12-06 Astrazeneca Ab Nouvelle forme cristalline et amorphe d'un compose de triazolo(4,5-d)pyrimidine
US20080045548A1 (en) 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
WO2011076749A2 (fr) 2009-12-23 2011-06-30 Ratiopharm Gmbh Forme solide de dosage pharmaceutique
US8425934B2 (en) 2006-08-21 2013-04-23 Astrazeneca Ab Pharmaceutical compositions
WO2013150495A2 (fr) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Préparation de ticagrelor
WO2014006091A1 (fr) * 2012-07-04 2014-01-09 Lek Pharmaceuticals D.D. Produits d'addition de ticagrelor et de sels métalliques divalents
WO2014118808A2 (fr) * 2013-02-04 2014-08-07 Hetero Research Foundation Dispersion solide de ticagrelor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034283A1 (fr) 1998-12-04 2000-06-15 Astrazeneca Ab Nouveaux composes de triazolo(4,5-d)pyrimidine
WO2001092262A1 (fr) * 2000-06-02 2001-12-06 Astrazeneca Ab Nouvelle forme cristalline et amorphe d'un compose de triazolo(4,5-d)pyrimidine
US7265124B2 (en) 2000-06-02 2007-09-04 Astrazeneca Ab Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
US20080045548A1 (en) 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
US8425934B2 (en) 2006-08-21 2013-04-23 Astrazeneca Ab Pharmaceutical compositions
WO2011076749A2 (fr) 2009-12-23 2011-06-30 Ratiopharm Gmbh Forme solide de dosage pharmaceutique
WO2013150495A2 (fr) * 2012-04-05 2013-10-10 Dr. Reddy's Laboratories Limited Préparation de ticagrelor
WO2014006091A1 (fr) * 2012-07-04 2014-01-09 Lek Pharmaceuticals D.D. Produits d'addition de ticagrelor et de sels métalliques divalents
WO2014118808A2 (fr) * 2013-02-04 2014-08-07 Hetero Research Foundation Dispersion solide de ticagrelor

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832683A (zh) * 2015-01-15 2016-08-10 成都国弘医药有限公司 一种含有替格瑞洛的片剂
WO2017182455A1 (fr) 2016-04-18 2017-10-26 Amneal Pharmaceuticals Company Gmbh Composition pharmaceutique stable de ticagrelor amorphe
CN108078944A (zh) * 2016-11-22 2018-05-29 重庆植恩药业有限公司 含有替格瑞洛的固体组合物及其制备方法
EP3332769A1 (fr) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques orales solides de ticagrelor
WO2018104363A1 (fr) 2016-12-07 2018-06-14 Sanovel Ilac Sanayi Ve Ticaret A.S. Compositions pharmaceutiques orales solides de ticagrelor
CN107397717A (zh) * 2017-09-13 2017-11-28 冯威 一种替卡格雷或其药学上可接受盐的固体制剂
WO2019170244A1 (fr) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Formulation de comprimé contenant du ticagrelor
CN110507624A (zh) * 2018-05-22 2019-11-29 江苏恒瑞医药股份有限公司 一种替格瑞洛或其盐的控释组合物
WO2020021110A1 (fr) 2018-07-27 2020-01-30 Krka, D.D., Novo Mesto Composition pharmaceutique de ticagrélor
CN111450067A (zh) * 2019-01-18 2020-07-28 北京万全德众医药生物技术有限公司 一种替格瑞洛分散片及其制备方法

Similar Documents

Publication Publication Date Title
WO2015001489A1 (fr) Compositions pharmaceutiques de ticagrélor
EP2180882B2 (fr) Préparation pharmaceutique à matrice solide
EP3110402A1 (fr) Compositions de dapagliflozin
EP3120871B1 (fr) Dispersion solide
WO2013030789A1 (fr) Forme pharmaceutique orale solide contenant un inhibiteur pde-iv faiblement soluble dans l'eau
WO2017182455A1 (fr) Composition pharmaceutique stable de ticagrelor amorphe
KR102473372B1 (ko) 알킬황산나트륨을 포함하는 의약 조성물
EP2676660A1 (fr) Compositions de prévention de l'hypertension
WO2015110952A1 (fr) Compositions pharmaceutiques orales solides comprenant du ticagrelor ou un sel de ce dernier
AU2014225449B2 (en) Stabilization of moisture-sensitive drugs
JP2018154596A (ja) アジルサルタン含有固形医薬組成物
JP2019512537A (ja) ダパグリフロジンの医薬組成物
KR101923403B1 (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
JPWO2017170854A1 (ja) 有効成分の化学的安定性に優れたフィルムコーティング錠
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
CA2905423A1 (fr) Comprimes de sovaprevir
WO2014058047A1 (fr) Procédé de production de préparation pharmaceutique contenant un inhibiteur calcique / antagoniste du récepteur d'angiotensine ii
EP2340834A1 (fr) Solubilité améliorée de la ziprasidone
EP3925601B1 (fr) Formulation gastro-résistante contenant du posaconazole et un inhibiteur de précipitation polymère
US20090264460A1 (en) Clopidogrel pharmaceutical formulations
WO2021106004A1 (fr) Composition pharmaceutique de s-adénosylméthionine
WO2018029262A1 (fr) Composition pharmaceutique solide comprenant du sofosbuvir amorphe.
WO2018229785A1 (fr) Compositions pharmaceutiques de ticagrélor
WO2014115082A1 (fr) Formulations pharmaceutiques d'imatinib
CA2988267A1 (fr) Capsules de capecitabine a liberation prolongee

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14738641

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14738641

Country of ref document: EP

Kind code of ref document: A1